Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition
Candela Cives-Losada·Óscar Briz·Elisa Lozano·Laura Zanatto·Pau Sancho‐Bru·Maria Luz Martínez‐Chantar·Matías A. Ávila·Carolina Armengol·Stefano Cairo·Jose J. G. Marin·Rocio I. R. Macias
Hepatoblastoma (HB) is the most common malignant liver tumor in children. One-fifth of patients exhibit a poor prognosis due to resistance to conventional chemotherapy, which typically includes doxorubicin. One of the underlying mechanisms is drug efflux through the MDR1 export pump. This study aims to explore pharmacological strategies for sensitizing HB by inhibiting MDR1. A panel of compounds, including established MDR1 inhibitors, natural products, clinically used drugs, and tyrosine kinase